Kandori fleck retina

Summary

Kandori fleck retina (MONDO:0009236) is a disease. A subtype of familial flecked retinopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Kandori fleck retina
Mondo ID	MONDO:0009236
MeSH	C562701
OMIM	228990
Orphanet	99179
ICD-11	697904956
SNOMED CT	765191009
UMLS	C0271257
MedGen	78764
GARD	0016900
Is cancer (heuristic)	no

Disease family

This is a subtype of familial flecked retinopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal degeneration › inherited retinal dystrophy › hereditary macular dystrophy › familial flecked retinopathy › Kandori fleck retina

Related subtypes (4): Doyne honeycomb retinal dystrophy, fundus albipunctatus, Bietti crystalline corneoretinal dystrophy, Stargardt disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.